Development of an Efficient Alternative Synthesis of the Endothelin Receptor Antagonist Bosentan

IF 1.2 4区 化学 Q4 CHEMISTRY, ORGANIC
Jigar Panchal , Namita Misra , Meenu Devi , Ashima Sharma , Sonika Jain , Pankaj Jain , Jaya Dwivedi , Swapnil Sharma
{"title":"Development of an Efficient Alternative Synthesis of the Endothelin Receptor Antagonist Bosentan","authors":"Jigar Panchal , Namita Misra , Meenu Devi , Ashima Sharma , Sonika Jain , Pankaj Jain , Jaya Dwivedi , Swapnil Sharma","doi":"10.1080/00304948.2023.2170665","DOIUrl":null,"url":null,"abstract":"Pulmonary artery hypertension (PAH), is characterized by pulmonary vascular resistance that may lead to heart failure. 1 – 2 Endothelin receptor antagonists (ERAs) have been considered as rational targets in the therapy of PAH. 3 Bosentan monohydrate (brand name Tracleer V R ) is the first orally administered drug approved by the U.S. Food and Drug Administration indicated for the therapy of PAH. 4 Bosentan (4-( tert -butyl)- N -(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-[2,2 ’ -bipyrimidin]-4-yl)benzenesulfonamide (","PeriodicalId":19681,"journal":{"name":"Organic Preparations and Procedures International","volume":"55 5","pages":"Pages 404-410"},"PeriodicalIF":1.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Organic Preparations and Procedures International","FirstCategoryId":"92","ListUrlMain":"https://www.sciencedirect.com/org/science/article/pii/S0030494823000205","RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, ORGANIC","Score":null,"Total":0}
引用次数: 0

Abstract

Pulmonary artery hypertension (PAH), is characterized by pulmonary vascular resistance that may lead to heart failure. 1 – 2 Endothelin receptor antagonists (ERAs) have been considered as rational targets in the therapy of PAH. 3 Bosentan monohydrate (brand name Tracleer V R ) is the first orally administered drug approved by the U.S. Food and Drug Administration indicated for the therapy of PAH. 4 Bosentan (4-( tert -butyl)- N -(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-[2,2 ’ -bipyrimidin]-4-yl)benzenesulfonamide (
内皮素受体拮抗剂波生坦高效替代合成方法的研究
肺动脉高压(PAH)的特点是肺血管阻力可能导致心力衰竭。1–2内皮素受体拮抗剂(ERAs)被认为是治疗PAH的合理靶点。3波生坦一水合物(商标名Tracleer V R)是美国食品药品监督管理局批准的第一种用于治疗PAH的口服药物。4-波生坦(4-(叔丁基)-N-(6-(2-羟基乙氧基)-5-(2-甲氧基苯氧基)-[2,2'-双嘧啶]-4-基)苯磺酰胺(
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.60
自引率
13.30%
发文量
60
审稿时长
2 months
期刊介绍: Organic Preparations and Procedures International (OPPI) publishes important, bimonthly research relevant to organic chemists engaged in synthesis. It is devoted to preparative organic chemistry, organometallic compounds, and procedures generally related to synthesis. The mission has always been to assist the practitioner by publishing reliable and reproducible procedures of the highest standards. OPPI publishes articles in every area of preparative organic chemistry - from innovative technology to improvements in traditional synthesis. Along with experimental papers, the Journal publishes authoritative reviews on significant topics in synthesis. The editors work closely with all authors, including those whose first language may not be English, to ensure important work is provided with clarity and a forum, giving OPPI a truly unique opportunity to serve a worldwide audience with valuable material.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信